These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 22776144)
41. Epidemiological survey of preinvasive breast cancer. Vandenbroucke A; Bourdon C Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():3-10. PubMed ID: 8298449 [TBL] [Abstract][Full Text] [Related]
42. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897 [TBL] [Abstract][Full Text] [Related]
43. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. Giricz O; Reynolds PA; Ramnauth A; Liu C; Wang T; Stead L; Childs G; Rohan T; Shapiro N; Fineberg S; Kenny PA; Loudig O J Pathol; 2012 Jan; 226(1):108-19. PubMed ID: 21953071 [TBL] [Abstract][Full Text] [Related]
44. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ. Ringberg A; Palmer B; Linell F; Rychterova V; Ljungberg O Eur J Surg Oncol; 1991 Feb; 17(1):20-9. PubMed ID: 1847343 [TBL] [Abstract][Full Text] [Related]
45. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Ottesen GL; Graversen HP; Blichert-Toft M; Christensen IJ; Andersen JA Breast Cancer Res Treat; 2000 Aug; 62(3):197-210. PubMed ID: 11072784 [TBL] [Abstract][Full Text] [Related]
46. Amplification of the prolactin receptor gene in mammary lobular neoplasia. Tran-Thanh D; Arneson NC; Pintilie M; Deliallisi A; Warren KS; Bane A; Done SJ Breast Cancer Res Treat; 2011 Jul; 128(1):31-40. PubMed ID: 20658264 [TBL] [Abstract][Full Text] [Related]
47. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up. Mahoney MC; Robinson-Smith TM; Shaughnessy EA AJR Am J Roentgenol; 2006 Oct; 187(4):949-54. PubMed ID: 16985141 [TBL] [Abstract][Full Text] [Related]
48. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies. Renshaw AA; Gould EW Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205 [TBL] [Abstract][Full Text] [Related]
49. Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Nakhlis F; Harrison BT; Giess CS; Lester SC; Hughes KS; Coopey SB; King TA Ann Surg Oncol; 2019 Jan; 26(1):55-61. PubMed ID: 30362065 [TBL] [Abstract][Full Text] [Related]
50. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. Mullooly M; Khodr ZG; Dallal CM; Nyante SJ; Sherman ME; Falk R; Liao LM; Love J; Brinton LA; Gierach GL Am J Epidemiol; 2017 Dec; 186(12):1329-1340. PubMed ID: 28637226 [TBL] [Abstract][Full Text] [Related]
52. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Berg WA; Mrose HE; Ioffe OB Radiology; 2001 Feb; 218(2):503-9. PubMed ID: 11161169 [TBL] [Abstract][Full Text] [Related]
53. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Jacobs TW; Pliss N; Kouria G; Schnitt SJ Am J Surg Pathol; 2001 Feb; 25(2):229-36. PubMed ID: 11176072 [TBL] [Abstract][Full Text] [Related]
55. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Vos CB; Cleton-Jansen AM; Berx G; de Leeuw WJ; ter Haar NT; van Roy F; Cornelisse CJ; Peterse JL; van de Vijver MJ Br J Cancer; 1997; 76(9):1131-3. PubMed ID: 9365159 [TBL] [Abstract][Full Text] [Related]
56. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Shin SJ; Rosen PP Arch Pathol Lab Med; 2002 Jun; 126(6):697-701. PubMed ID: 12033958 [TBL] [Abstract][Full Text] [Related]
57. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886 [TBL] [Abstract][Full Text] [Related]
58. Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β. Raap M; Gronewold M; Christgen H; Glage S; Bentires-Alj M; Koren S; Derksen PW; Boelens M; Jonkers J; Lehmann U; Feuerhake F; Kuehnle E; Gluz O; Kates R; Nitz U; Harbeck N; Kreipe HH; Christgen M Lab Invest; 2018 Jan; 98(1):117-129. PubMed ID: 29035379 [TBL] [Abstract][Full Text] [Related]
59. [Carcinoma in situ of the breast]. Laenkholm AV; Hoffmann J; Rank FE Ugeskr Laeger; 2007 Sep; 169(37):3087-90. PubMed ID: 17877955 [TBL] [Abstract][Full Text] [Related]
60. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ciocca RM; Li T; Freedman GM; Morrow M Ann Surg Oncol; 2008 Aug; 15(8):2263-71. PubMed ID: 18506537 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]